+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Scopolamine Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4987198
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
UP TO OFF
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Baxter International Inc.
  • GlaxoSmithKline plc.
  • Myungmoon Pharm Co Ltd
  • Novartis International AG
  • Perrigo Company plc
  • Pfizer Inc.
  • MORE
The market studied is expected to witness CAGR of 6% over the forecast period. The market growth is attributed to the increasing prevalence of motion sickness and growing awareness among the population. Psychological stress is one of the major contributing factors of motion sickness. These psychological factors affect intestinal sensitivity and alteration in the central nervous system. Also, the introduction of novel drug delivery systems such as transdermal patches and adaptation of these dosage forms are expected to bolster the market growth over the forecast period.

Furthermore, the growing number of travellers across the globe, increasing number of surgeries due to chronic conditions is expected to boost the market growth. However, misuse of scopolamine, side effects and stringent regulatory policies are expected to hamper the market growth over the forecast period.

Key Market Trends

Transdermal Patches Anticipated to Grow at Significant Rate

Transdermal patches are widely used nowadays in the treatment of motion sickness. The transdermal patches are prefered due to ease of use, cost-effectiveness and availability. The patch is applied to the hairless skin behind the ear and is used to treat the motion sickness caused by the anaesthesia during the surgeries. According to the world health organization, about 234.2 million major surgeries are performed around the globe every year. Owing to the growing number of surgical interventions across the globe coupled with the launch of new products, the market for transdermal scopolamine patches are expected to grow at a significant rate.

Also, the growing number of domestic and international travellers around the globe and the usage of scopolamine to treat motion sickness during travelling expected to boost market growth over the forecast period.

North America is Expected to have Significant Market Share

North America region is anticipated to have significant market share owing to well-established healthcare infrastructure and the presence of key market players. Also, a growing number of surgeries in the region, an increasing number of travellers coupled with product launches are anticipated to boost the market growth over the forecast period. According to the U.S. Travel Association, U.S. domestic travel has increased by 1.9% in 2018, a total of 2.3 billion person-trips. The Asia Pacific region is expected to grow at significant rates owing to increased expenditure on healthcare, presence of medium and small-sized market players and growing medical tourism for the surgeries in the region.

Competitive Landscape

Global scopolamine market is moderately fragmented and competitive. Market players are focusing on new product launches, product innovations and geographical expansion. The companies operating in the market include Pfizer Inc., Baxter International Inc., Myungmoon Pharm Co Ltd., and Alchem International Pvt. Ltd. among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Baxter International Inc.
  • GlaxoSmithKline plc.
  • Myungmoon Pharm Co Ltd
  • Novartis International AG
  • Perrigo Company plc
  • Pfizer Inc.
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Number of Surgical Interventions due to Chronic Diseases
4.2.2 Rising Healthcare Expenditure and Adaptation of Scopolamine
4.3 Market Restraints
4.3.1 Side Effects and Misuse of Scopolamine
4.3.2 Stringent Regulatory Policies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Dosage Form
5.1.1 Injectables
5.1.2 Tablets
5.1.3 Transdermal Patches
5.1.4 Others
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Baxter International Inc.
6.1.3 Myungmoon Pharm Co Ltd
6.1.4 Alchem International Pvt. Ltd.
6.1.5 Caleb Pharmaceuticals, Inc.
6.1.6 GlaxoSmithKline plc.
6.1.7 Phytex Australia
6.1.8 Fine Chemicals Corporation
6.1.9 Perrigo Company plc
6.1.10 Novartis International AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer Inc.
  • Baxter International Inc.
  • Myungmoon Pharm Co Ltd
  • Alchem International Pvt. Ltd.
  • Caleb Pharmaceuticals, Inc.
  • GlaxoSmithKline plc.
  • Phytex Australia
  • Fine Chemicals Corporation
  • Perrigo Company plc
  • Novartis International AG
Note: Product cover images may vary from those shown
Adroll
adroll